Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Statement [Abstract]
Net revenues	$ 177,026	$ 82,888	$ 33,087
Cost of revenues	55,609	39,870	20,610
Impairment of field equipment		6,412
Gross profit	121,417	36,606	12,477
Operating costs and expenses:
Research, development and clinical trials	38,103	41,467	43,748
Sales and marketing	63,528	59,449	38,861
General and administrative	59,114	51,007	33,864
Total operating costs and expenses	160,745	151,923	116,473
Operating loss	(39,328)	(115,317)	(103,996)
Financial expenses, net	(9,169)	(6,147)	(3,151)
Loss before income taxes	(48,497)	(121,464)	(107,147)
Income taxes	13,165	10,381	4,434
Net loss	$ (61,662)	$ (131,845)	$ (111,581)
Basic and diluted net loss per ordinary share	$ (0.70)	$ (1.54)	$ (3.67)
Weighted average number of ordinary shares used in computing basic and diluted net loss per share	88,546,719	85,558,448	30,401,603